Wall Street analysts expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report sales of $3.08 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $4.27 million. The business is scheduled to announce its next quarterly earnings results on Monday, March 9th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year sales of $7.99 million for the current fiscal year, with estimates ranging from $7.40 million to $9.17 million. For the next fiscal year, analysts expect that the company will report sales of $29.61 million, with estimates ranging from $17.16 million to $46.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its earnings results on Thursday, November 7th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.
Shares of NASDAQ KALA traded down $0.13 during trading on Friday, hitting $3.99. The company had a trading volume of 92,828 shares, compared to its average volume of 247,863. The stock has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.71. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25. Kala Pharmaceuticals has a 12 month low of $3.24 and a 12 month high of $9.25. The firm has a market capitalization of $137.83 million, a P/E ratio of -1.61 and a beta of 2.21.
Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Kala Pharmaceuticals by 148.5% during the 2nd quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock valued at $26,000 after buying an additional 2,399 shares in the last quarter. Greenwich Wealth Management LLC increased its stake in Kala Pharmaceuticals by 28.7% during the second quarter. Greenwich Wealth Management LLC now owns 13,000 shares of the company’s stock worth $83,000 after acquiring an additional 2,900 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after acquiring an additional 5,806 shares during the last quarter. Marshall Wace LLP purchased a new stake in Kala Pharmaceuticals during the first quarter valued at approximately $325,000. Finally, Charles Schwab Investment Management Inc. raised its position in Kala Pharmaceuticals by 34.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock valued at $328,000 after purchasing an additional 13,271 shares during the period. Hedge funds and other institutional investors own 64.21% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: Options Trading – What is a Straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.